| Literature DB >> 20088117 |
T Tawadros1, A Doerfler, C Treuthardt, V Praz, F Levi, A Zouhair, D Berthold, J Bauer, C Iselin, P Jichlinski.
Abstract
Prostate cancer screening using PSA is controversial because of a low specificity and detection of non clinically relevant cancer. Two important studies have been published recently. One of two studies suggests a 20% lowering in specific prostate cancer mortality due to PSA screening. This benefit is relevant but implies at a high risk of overtreatment and treatment-related complications. Currently PSA screening is only proposed as an individual screening for informed patients.Entities:
Mesh：
Substances：
Year: 2009 PMID： 20088117
Source DB: PubMed Journal: Rev Med Suisse ISSN： 1660-9379